Statute Details
- Title: Medicines (Licensing, Standard Provisions and Fees) Regulations
- Act Code: MA1975-RG6
- Legislative Type: Subsidiary legislation (sl)
- Commencement: (Not provided in the extract; the regulations are part of the Medicines Act licensing framework)
- Current Version: Current version as at 27 Mar 2026
- Authorising Act: Medicines Act (Cap. 176), Section 74
- Citation: Medicines (Licensing, Standard Provisions and Fees) Regulations (Rg 6); G.N. No. S 174/1987
- Key Sections (from extract): Section 2 (definitions); Section 3 (standard provisions); Section 4 (grant of licences); Section 5 (fees); Section 5A (cost of evaluation); Section 6 (offences)
- Schedules: First Schedule (product licence standard provisions); Second Schedule (import licence standard provisions); Third Schedule (wholesale dealer’s licence standard provisions); Fourth Schedule (manufacturer’s licence standard provisions); Fifth Schedule (fees); Sixth Schedule (repealed)
What Is This Legislation About?
The Medicines (Licensing, Standard Provisions and Fees) Regulations (“the Regulations”) sit under Singapore’s Medicines Act and provide the operational rules for licensing medicinal products and related activities. In plain terms, the Regulations tell licence applicants and licence holders what conditions are automatically attached to different types of licences, what fees apply, and what compliance failures amount to offences.
The Regulations do not, by themselves, create the substantive “medicine control” regime (such as whether a particular product may be sold). Instead, they implement the licensing architecture by prescribing “standard provisions” for licences granted under Part II of the Medicines Act. These standard provisions are set out in schedules and are tailored to the licence type: product licences, import licences, wholesale dealer’s licences, and manufacturer’s licences.
A notable feature of the Regulations is that they include special standard provisions for Chinese proprietary medicines (a category defined by reference to other legislation). For these medicines, the Regulations modify the standard import, wholesale, and manufacturer licence conditions, including additional documentation and testing requirements tied to microbiological and other safety parameters.
What Are the Key Provisions?
1. Definitions and regulatory actors (Section 2)
Section 2 defines key terms used throughout the Regulations. For practitioners, the most important definitions include: “licensing authority” (the Chief Executive of the Authority), “Authority’s website” (used for publication and listing of regulatory information), and regulatory concepts such as “competent drug regulatory agency” and “reference drug regulatory agency” (relevant to how regulatory decisions may be relied upon or referenced). The definition of “major variation” is also significant because it frames what kinds of changes to a medicinal product are treated as substantial—typically relevant to how licensing and approvals are managed.
2. Standard provisions for licences (Section 3)
Section 3 is the core mechanism of the Regulations. It provides that, subject to limited exceptions, the standard provisions for licences (including provisional licences) granted under Part II of the Medicines Act are the provisions set out in the relevant schedules. This means that licence conditions are not reinvented for each licence; instead, the schedules supply a baseline of regulatory obligations.
Section 3 also contains special modifications for Chinese proprietary medicines. The extract shows that for import licences relating to Chinese proprietary medicines, the standard provisions in the Second Schedule apply except for specified paragraphs, and additional conditions are inserted. These include: (i) a requirement to seek prior approval from the licensing authority to deal with any medicinal product under the licence; (ii) an obligation to provide information and documents within the time specified by the authority; and (iii) restrictions on importing, selling, or supplying unless the approval remains valid and the holder complies with all written laws applicable to the product.
3. Additional documentation and testing for Chinese proprietary medicines (Section 3(2)(d))
A particularly practical and compliance-heavy part of the Regulations is the requirement that, within 2 months of the import of the consignment, the licence holder must submit specified declarations and test results. The extract indicates that the required submissions include:
- Declaration of absence of poison (as defined in the Poisons Act) and absence of any synthetic active substance in the medicinal product.
- Test results on the content of substances specified in the Medicines (Prohibition of Sale and Supply) Order (O 4).
- Microbiological testing depending on route of administration:
- Oral consumption: test results for Escherichia coli, Salmonella, Staphylococcus aureus, total yeast and mould count, and total aerobic microbial count per gram or millilitre (with an exception where the product contains active substances derived from plants/animals and produced by fermentation processes).
- External application: test results for Pseudomonas aeruginosa, Staphylococcus aureus, total yeast and mould count, and total aerobic microbial count per gram or millilitre (with a similar fermentation-process exception).
- Other documents and test results as the licensing authority may require.
For lawyers advising importers or licence holders, these requirements are important because they create a time-bound post-import compliance obligation. Failure to submit within the specified period, or submission of inadequate test results, can expose the holder to enforcement action and potentially offences under the Regulations (see Section 6).
4. Grant of licences and the role of standard provisions (Section 4)
Section 4 provides that every product licence, wholesale dealer’s licence, and manufacturer’s licence granted shall be subject to the standard provisions. While the extract truncates the remainder of Section 4, the legal effect is clear: the schedules’ standard provisions become conditions of the licences. This is a key point for practitioners because it means that compliance is not limited to what is written in a licence letter; the statutory standard provisions operate as embedded conditions.
5. Fees and evaluation costs (Section 5 and Section 5A)
The Regulations set out the fees payable for applications for, and the grant of, licences and certificates, and for related administrative steps. The extract also indicates a provision for cost of evaluation (Section 5A). In practice, this matters for budgeting and for advising clients on the total cost of obtaining and maintaining authorisations.
6. Offences for contravention or failure to comply (Section 6)
Section 6 addresses enforcement by creating offences where a licence holder contravenes or fails to comply with any standard provision applicable to the holder. This provision is central to risk management: it converts regulatory conditions into legally enforceable obligations. For counsel, the focus should be on mapping each client’s licence type to the relevant schedule and then to the specific standard provisions that apply.
How Is This Legislation Structured?
The Regulations are structured as follows:
- Part/Sections: The main operative sections are Sections 1 to 6 (with Section 1 being the citation and Section 2 definitions).
- Section 3 (Standard provisions): The “gateway” provision that imports the schedules into the licensing regime, including special modifications for Chinese proprietary medicines.
- Section 4 (Grant of licences): Confirms that licences granted are subject to the standard provisions.
- Section 5 and Section 5A (Fees and evaluation costs): Establishes the fee framework and evaluation cost mechanism.
- Section 6 (Offences): Provides the offence hook for non-compliance.
- Schedules:
- First Schedule: Standard provisions for product licences.
- Second Schedule: Standard provisions for import licences (with modifications for Chinese proprietary medicines under Section 3(2)).
- Third Schedule: Standard provisions for wholesale dealer’s licences (with modifications for Chinese proprietary medicines under Section 3(3)).
- Fourth Schedule: Standard provisions for manufacturer’s licences (with modifications for Chinese proprietary medicines under Section 3(4)).
- Fifth Schedule: Fees.
- Sixth Schedule: Repealed.
Who Does This Legislation Apply To?
The Regulations apply to persons and businesses that seek or hold licences under Part II of the Medicines Act. This includes entities involved in the lifecycle of medicinal products: product authorisation (product licences), cross-border movement (import licences), distribution (wholesale dealer’s licences), and production (manufacturer’s licences).
Special attention is required for licence holders dealing with Chinese proprietary medicines. For these medicines, the standard provisions for import, wholesale dealing, and manufacturing are modified, including additional prior approval requirements and specific documentation and testing obligations after import. Practitioners should therefore verify not only the licence type but also the product category to determine the correct set of standard provisions.
Why Is This Legislation Important?
For practitioners, the Regulations are important because they provide the compliance “baseline” that attaches to licences. The schedules operate like a statutory contract of conditions: once a licence is granted, the holder is expected to comply with the standard provisions, and contraventions can trigger offences under Section 6.
The Regulations also have a direct operational impact. The Chinese proprietary medicine provisions demonstrate how licensing conditions translate into concrete compliance tasks—such as microbiological testing, declarations regarding poison and synthetic active substances, and submission of test results within a strict post-import timeframe. These are not merely administrative formalities; they affect whether the licence holder can lawfully import, sell, or supply the relevant products.
Finally, the fee and evaluation cost provisions matter for commercial planning and for advising clients on the total regulatory cost of licensing. Where evaluation costs apply, counsel should ensure that clients understand the likely cost drivers and the timing implications of applications and approvals.
Related Legislation
- Medicines Act (Cap. 176), including Section 74 (authorising provision for these Regulations)
- Poison Act (Cap. 234) (definition of “poison” referenced in Chinese proprietary medicine import conditions)
- Medicines (Prohibition of Sale and Supply) Order (O 4) (substances for which test results are required)
- Medicines (Traditional Medicines, Homoeopathic Medicines and other Substances) (Exemption) Order (O 6) (definition reference for “Chinese proprietary medicine”)
- Medicines (Export Licence for Psychotropic Substances) Regulations (Rg 9) (definition reference for “psychotropic substance”)
Source Documents
This article provides an overview of the Medicines (Licensing, Standard Provisions and Fees) Regulations for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.